



ABOUT ARRAY BIOPHARMA



Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a *BRAF*^{V600E} or *BRAF*^{V600K} mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in *BRAF*-mutant colorectal cancer. Array's pipeline includes several additional programs currently in registration trials being advanced by us or current license-holders.

BY THE NUMBERS



NASDAQ	ARRY
Market Capitalization	>\$3B
Staff	300
Cash (9/30/18)	\$415.4M
Headquarters	Boulder, CO

www.arraybiopharma.com

Info@arraybiopharma.com

303.381.6600

3200 Walnut Street
Boulder, Colorado 80301

Follow us @arraybiopharma
on Twitter and LinkedIn

Maximizing Success of Encorafenib & Binimetinib is Array's Top Priority

Significant Pipeline Milestones Achieved...

... Important Value-Drivers

	<p>BRAFTOVI + MEKTOVI launched in US</p> <ul style="list-style-type: none"> Positive reception from U.S. melanoma healthcare providers COLUMBUS Phase 3 trial OS published in <i>Lancet Oncology</i> BRAFTOVI + MEKTOVI approved in Europe for advanced <i>BRAF</i>-mutant melanoma 	<ul style="list-style-type: none"> Marketing application in Japan under review Available for sale in Europe
<p>BRAF-MUTANT METASTATIC CRC (mCRC)</p>	<p>FDA granted Breakthrough Therapy Designation</p> <ul style="list-style-type: none"> Planned interim analysis based on consultation with FDA and EMA; analysis for U.S. sNDA based primarily on ORR and duration of response 	<ul style="list-style-type: none"> Complete enrollment expected around end of the year Plan to seek accelerated approval in the U.S. if supported by positive interim results Topline results 1H19
<p>ANCHOR CRC</p>	<p>Encorafenib + Binimetinib + Cetuximab in First-line <i>BRAF</i>^{V600E}-mutant mCRC</p>	<ul style="list-style-type: none"> Trial posted to ClinicalTrials.gov
<p>MSS CRC AND OTHER CANCERS</p>	<p>Binimetinib + I/O Collaborations</p>	

COST SHARING

BEACON CRC co-funding: Pierre Fabre (40%), Ono Pharmaceuticals (milestone payments), Merck KGaA (cetuximab supply)

Strategy

We are a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Our strategy includes:



Inventing best-in-class small molecule drugs for patient populations which have significant unmet medical need

Conducting clinical trials which maximize the overall value of our programs for patients and Array



Building and maintaining an oncology focused sales, marketing and medical organization to commercialize our products in the U.S

Selectively partnering with early-stage research programs outside oncology



Partnerships

ONO PHARMACEUTICAL CO., LTD.

AstraZeneca

Pierre Fabre

AMGEN

Genentech
A Member of the Roche Group

AsahiKASEI

LOXO
ONCOLOGY